Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNIK | Q9UKE5 | 8/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | CHKA | P35790 | 2/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | INSR | P06213 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.41 |
| ▸ | MERTK | Q12866 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3719893 | 0.91 | GSK3B (0.43) | DRD2DRD4DRD3CHKAGSK3B | |
| SCHEMBL3663103 | 0.90 | TGFBR1 (0.51) | DRD2DRD4DRD3TGFBR1GSK3B | |
| SCHEMBL3725755 | 0.90 | ABL1 (0.48) | DRD2DRD4DRD3TGFBR1MAP3K11 | |
| SCHEMBL3722539 | 0.89 | DRD2 (0.41) | TNIKDRD2DRD4DRD3CHKA | |
| SCHEMBL2305188 | 0.89 | TNIK (0.44) | TNIKDRD2DRD4DRD3CHKA | |
| SCHEMBL3727190 | 0.85 | CHEK1 (0.48) | DYRK1A | |
| SCHEMBL3715527 | 0.84 | DRD2 (0.40) | TNIKDRD2DRD4DRD3TGFBR1 | |
| SCHEMBL3718893 | 0.84 | DRD2 (0.40) | DRD2DRD4DRD3TGFBR1ABL1 | |
| SCHEMBL3726796 | 0.83 | ABL1 (0.46) | DRD2DRD4DRD3TGFBR1MAP3K11 | |
| SCHEMBL3721740 | 0.81 | TGFBR1 (0.42) | DRD2DRD4DRD3TGFBR1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242742-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-8343966-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-01-01 | — | — | US | disclosed |
| EP-2242742-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20090215776-A1 | Organic compounds | ADCOCK CLAIRE | 2009-08-27 | — | — | US | disclosed |
| WO-2009087212-A2 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215776-A1 | Organic compounds | REN, RXFP1, MYLK | TNIK 4213/4885DRD2 2577/4885DRD4 2342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.